Where our team of guest writers discuss what they think about the current NGP US Issues.
Karen Gotting-Smith tells NGP how AstraZeneca stays fighting fit in difficult times.
Next generation DNA sequencing instruments, introduced to the market in the past few years, are beginning to dominate the landscape of DNA sequencing projects – and rightfully so.
Bob Moore of GE Healthcare examines the benefits of contracting out scientific asset services.
Collaboration is more than just working together on shared documents. Collaboration is a fundamental aspect of the business that is present throughout the modern pharmaceutical organization. As companies transition to more distributed operations, and
The life sciences industry continues to be challenged by the competing demands of regulatory drivers, distribution requirements and changing patient demographics.